| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
Arnuity Ellipta is owned by Glaxosmithkline.
Arnuity Ellipta contains Fluticasone Furoate.
Arnuity Ellipta has a total of 14 drug patents out of which 3 drug patents have expired.
Expired drug patents of Arnuity Ellipta are:
- US5873360
- US7629335
- US7101866
Arnuity Ellipta was authorised for market use on 17 May, 2018.
Arnuity Ellipta is available in powder;inhalation dosage forms.
Arnuity Ellipta can be used as for once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older.
The generics of Arnuity Ellipta are possible to be released after 11 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-290) | Mar 01, 2026 |
| New Strength(NS) | May 17, 2021 |
| New Patient Population(NPP) | May 17, 2021 |
| New Product(NP) | Aug 20, 2017 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: For once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
